All News

The updated Prescription Drug User Fee Act date for zenocutuzumab in these indications is February 4, 2025.

Treatment with (Z)-endoxifen yielded no changes in hematological safety tests among patients enrolled on the phase 2 KARISMA-Endoxifen study.

Major clinical trials lack documentation and participation data on Native Hawaiians and Pacific Islanders, a recent study finds.

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Consolidative hematopoietic cell transplantation also confers improved progression-free survival among those with relapsed/refractory B-ALL.

Phase 3 data may support the photodynamic therapy as a noninvasive treatment option for patients with superficial basal cell carcinoma.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.

Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.

Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.

As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.

Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.

Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.

Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.

BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.

Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.

Patients with non–small cell lung cancer had a positive long-term benefit with perioperative chemoimmunotherapy, according to the 5-year NADIM trial update.

Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.

Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.

Two cases of patients with multiple myeloma and kidney failure successfully underwent CAR T-cell therapy using ciltacabtagene autoleucel.

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.

cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.